Low-flying airplanes over Hopewell and two other Virginia cities conducting research
It's part of research training conducted by NASA from June 22-26, the agency announced June 20. The two aircraft will take off from NASA's facility at Wallops Island on Virginia's Eastern Shore and conduct various maneuvers such as vertical spirals and flybys at altitudes between 1,000-10,000 feet, lower than most commercial airlines fly.
The planes will fly over such areas as power plants, landfills and urban centers. They will simulate missed approaches at airports and do flybys near runways to collect data on air pollutants and greenhouse gas emissions.
In Virginia, the planes — a P-3 Orion and a King Air B200 — will fly over Hopewell, Richmond and Hampton. Similar flights will take place in Baltimore and Philadelphia.
The following week, June 29-July 2, NASA will do the same flights over selected spots on the West Coast.
The flights are part of NASA's Student Airborne Research Program, an eight-week summer internship program where undergraduate students get hands-on experience in every aspect of a scientific campaign. According to the NASA announcement, students 'will assist in the operation of the science instruments on the aircraft to collect atmospheric data.'
'The SARP flights have become mainstays of NASA's Airborne Science Program, as they expose highly competitive STEM students to real-world data gathering within a dynamic flight environment,' Brian Bernth, chief of flight operations at NASA Wallops, said in a statement accompanying the announcement. 'Despite SARP being a learning experience for both the students and mentors alike, our P-3 is being flown and performing maneuvers in some of most complex and restricted airspace in the country. Tight coordination and crew resource management are needed to ensure that these flights are executed with precision but also safely.'
For more information about the SARP, visit the NASA website.
This article originally appeared on The Progress-Index: Planes will fly low over Hopewell as part of a student research program
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
NASA, Space-X scrub crew-11 launch due to weather
NASA and SpaceX canceled today's planned launch of the Crew-11 mission to the International Space Station due to cloud cover at the Kennedy Space Center launch site. They are now targeting 11:43 a.m. EDT on Friday, August 1, for liftoff of the SpaceX Falcon 9 rocket and Dragon spacecraft from Launch Complex 39A. The forecast currently shows a 75% chance of favorable weather at the launch site, though conditions along the Crew Dragon Endeavour flight path remain under review. NASA astronauts Zena Cardman and Mike Fincke, JAXA astronaut Kimiya Yui, and Roscosmos cosmonaut Oleg Platonov safely exited the spacecraft after the scrub. They returned to crew quarters to await their next launch attempt. Docking with the International Space Station is now targeted for approximately 3 a.m. EDT on Saturday, August 2. Click here to download our free news, weather and smart TV apps. And click here to stream Channel 9 Eyewitness News live. Solve the daily Crossword
Yahoo
2 hours ago
- Yahoo
NASA scrubs SpaceX launch amid ‘unfavorable' weather
(NEXSTAR) – A crewed mission on SpaceX's Dragon spacecraft was postponed due to 'an unfavorable weather forecast,' according to NASA. The launch was originally scheduled for 12:09 p.m. ET on Thursday. It has instead been rescheduled for Friday at 11:43 a.m. ET. 'Standing down from today's Falcon 9 launch of Dragon due to cloud cover at the launch site,' a representative for SpaceX explained on X. Largest digital camera ever built takes first shots of universe The crew of the mission — Zena Cardman and Mike Fincke of NASA, Kimiya Yui of Japan's Aerospace Exploration Agency, and Oleg Platonov of Russia's Roscosmos space program — are planning to arrive at the International Space Station this week to further study and experiment with methods to maintain the health of astronauts on future missions, including a possible expedition to Mars, according to NASA. 'Other science Crew-11 members will conduct on the space station include studying stem cell production methods to develop advanced cures, new ways to treat bacterial infections, and space agriculture techniques,' NASA says. On Thursday morning, the crew readied for their mission with a 'long-held spaceflight tradition,' according to NASA: a card game. 'The astronauts are not anything if they're not superstitious, so this is one of those traditions,' a representative for NASA says in a video of this morning's card game. 'The game changes every mission, it's really up to the chief of the office to figure out what that game is going to be. But the goal is the same: You go until the commander wins, and you have shaken off all of the bad luck, if you will.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
Yahoo
2 hours ago
- Yahoo
A single injection for newborns could protect them against HIV for years, study suggests
A single injection at birth could shield children from HIV for years, a study has suggested. The study is one of the first to show that the first weeks of life offer a critical window where the immune system is naturally more tolerant, meaning it is the optimal time to deliver gene therapies that would otherwise be rejected at older ages. Researchers hope the gene therapy jab could be used in the future to fight against paediatric infections in high-risk areas. 'Nearly 300 children are infected with HIV each day,' said first author Amir Ardeshir, associate professor of microbiology and immunology at the Tulane National Primate Research Center in the US. 'This approach could help protect newborns in high-risk areas during the most vulnerable period of their lives.' The study, published in the journal Nature, created a gene therapy that programs cells to produce HIV-fighting antibodies. An animal study that tested the injection on non-human primates found it protected them from infection for at least three years without the need for a booster shot. But this was only if the injection was administered in the first month of life. In comparison, those that received the gene therapy between eight and 12 weeks after birth did not tolerate the treatment, study authors explain. 'This is a one-and-done treatment that fits the critical time when these mothers with HIV in resource-limited areas are most likely to see a doctor,' Dr Ardeshir said. 'As long as the treatment is delivered close to birth, the baby's immune system will accept it and believe it's part of itself.' Globally, an estimated 1.3 million women and girls living with HIV become pregnant every year, according to the World Health Organization (WHO). But if they do not receive medication, the rate of transmission of HIV from the mother to her child either during pregnancy, labour, delivery or breastfeeding ranges between 15 per cent and 45 per cent, according to WHO data. Although antiviral treatments can suppress the virus and limit transmission, adherence to treatment and doctor visits decline after childbirth, particularly in areas with limited access to healthcare, the study authors noted. This gene therapy uses a harmless virus that can deliver genetic code to cells, but is different to a vaccine. This virus was injected into muscle cells and delivered instructions to produce antibodies that are capable of neutralising multiple strains of HIV. Researchers explained that previous studies have found repeated infusions of the injection are needed for it to work. But by injecting it into muscle cells, researchers say they become 'micro-factories that just keep producing these antibodies'. Newborns showed greater tolerance to the jab, which prevented infection during breastfeeding. However, older infants and juveniles were more likely to have produced anti-drug antibodies that shut down the treatment. In addition, exposing a foetus to the antibodies from the gene therapy before birth helps older infants accept the therapy. However, because it has only been tested on animals, researchers still do not know if it will work on human children. If successful, this treatment could dramatically reduce mother-to-child HIV transmission rates in high-risk regions such as sub-Saharan Africa, where 90 per cent of paediatric HIV cases can be found. 'Nothing like this was possible to achieve even 10 years ago,' Dr Ardeshir said. 'This was a huge result, and now we have all the ingredients to take on HIV.'
